PD-1 and PD-L1 Inhibitors are playing a pivotal role in cancer management treatment. PD-1 and PD-L1 Inhibitors therapy is a specialized and targeted treatment that acts via blocking the activity of PD-1 and PD-L1 immune checkpoint proteins from the surface of cells. PD-1 and PD-L1 Inhibitors have accounted for proven effectiveness and satisfactory results in the treatment of cancer. Increasing cases for cancer patients across the globe and rising focus on specific & effective cancer management treatments are propelling the demand for oncology drugs and boosting the market for global PD-1 and PD-L1 Inhibitors market. Increasing emphasis on effective cancer treatment and rising economic burden due to cancer treatment procedures has led pharmaceutical manufacturers to invest significantly in research and development activities to fulfill the existing and latent demand for oncology drugs.
The Global PD-1 and PD-L1 Inhibitors market size is valued at US$ 22,076.9 Million, and it is expected to reach US$ XX Million in 2030, recording a promising CAGR of 15.6% during the period of 2019-2030. By region, in 2019, North America dominates the market with a share of XX % of the global PD-1 and PD-L1 Inhibitors market. US is the key market, holding the majority of the market for PD-1 and PD-L1 Inhibitors in the region.
The Global PD-1 and PD-L1 Inhibitors market is categorized on the basis of drug type, disease type, and region. On the basis of drug type, the market is segmented into Atezolizumab, Avelumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab, Sintilimab, and Others (Pipeline). On the basis of Indication Type, the market is segmented into Colorectal Cancer, Hodgkins Lymphoma, Melanoma, Merkel Cell Carcinoma, Non-Small-Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma, Urothelial Bladder Cancer, and Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among all, North America is expected to dominate the market during the analysis of forecast period.
The key players of this market include Merck Co., Bristol-Myers Squibb, Roche, AstraZeneca, Pfizer, Jiangsu HengRui Medicine, Regeneron Pharmaceuticals, ONO PHARMACEUTICAL CO., LTD., Eli Lilly and Company, Innovent Biologics, Inc., BeiGene, Junshi Biosciences Co., Biocad, 4D pharma plc., Agenus Inc., Calithera., Curis, Inc., Constellation Pharmaceuticals, Inc., Compass Therapeutics, Corvus Pharmaceuticals, CytomX Therapeutics, Inc., eFFECTOR Therapeutics, Inc., Jounce Therapeutics, Inc., MacroGenics, Inc., Mirati Therapeutics, Inc. , Moderna, Inc., MultiVir, Inc., NovoCure Ltd., NeoImmuneTech, Inc., Syndax Pharmaceuticals, PrimeVax Immuno-Oncology Inc., Incyte Corporation, Trillium Therapeutics Inc., and other prominent players.
